Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.
AUTOR(ES)
Pepin, J M
RESUMO
We were able to rapidly determine the susceptibility of human cytomegalovirus to ganciclovir using a late antigen synthesis reduction assay directly on primocultures of clinical specimens. This test was compared with a conventional susceptibility assay which was performed with cell-free virus obtained after cytomegalovirus isolation and in vitro passages. Both tests produced similar results. The rapid test, unlike conventional assays, is able to provide a result within 5 days after receipt of the specimen and could thus play a direct role in the therapeutic decision.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=270552Documentos Relacionados
- Rapid Ganciclovir Susceptibility Assay Using Flow Cytometry for Human Cytomegalovirus Clinical Isolates
- Flow Cytometric Determination of Ganciclovir Susceptibilities of Human Cytomegalovirus Clinical Isolates
- Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.
- Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma.
- Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus.
